Insider Transactions in Q1 2025 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2025
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-1.38%
|
$57,500
$115.04 P/Share
|
|
Feb 13
2025
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,551
-3.76%
|
$179,916
$116.79 P/Share
|
|
Feb 13
2025
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,910
+6.59%
|
-
|
|
Feb 13
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
5,844
-0.56%
|
$677,904
$116.69 P/Share
|
|
Feb 13
2025
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,979
+1.03%
|
-
|
|
Feb 13
2025
|
Stephen A Sherwin Director |
SELL
Open market or private sale
|
Direct |
13,831
-56.44%
|
$1,604,396
$116.69 P/Share
|
|
Feb 13
2025
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,605
+4.12%
|
-
|
|
Feb 13
2025
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,718
-2.43%
|
$199,288
$116.82 P/Share
|
|
Feb 13
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,879
-7.62%
|
$333,964
$116.79 P/Share
|
|
Feb 13
2025
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,407
+12.52%
|
-
|
|
Feb 13
2025
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,184
-2.48%
|
$253,344
$116.76 P/Share
|
|
Feb 13
2025
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,100
+4.45%
|
-
|
|
Feb 13
2025
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,558
-0.91%
|
$296,728
$116.85 P/Share
|
|
Feb 13
2025
|
Kyle Gano Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,807
+1.68%
|
-
|
|
Feb 13
2025
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
1,471
-14.34%
|
$170,636
$116.71 P/Share
|
|
Feb 13
2025
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,759
+21.2%
|
-
|
|
Feb 13
2025
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,785
-21.98%
|
$207,060
$116.74 P/Share
|
|
Feb 13
2025
|
David W. Boyer Chief Corp. Affairs Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,352
+29.09%
|
-
|
|
Feb 13
2025
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,558
-3.5%
|
$296,728
$116.86 P/Share
|
|
Feb 13
2025
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,807
+6.17%
|
-
|
|
Feb 13
2025
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,154
-2.38%
|
$249,864
$116.72 P/Share
|
|
Feb 13
2025
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,044
+4.27%
|
-
|
|
Feb 12
2025
|
Darin Lippoldt Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
190
-0.46%
|
-
|
|
Feb 10
2025
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
700
-3.58%
|
$82,600
$118.28 P/Share
|
|
Feb 10
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
2,274
-0.44%
|
$268,332
$118.37 P/Share
|
|
Feb 10
2025
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
980
-2.86%
|
$115,640
$118.22 P/Share
|
|
Feb 10
2025
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
700
-25.95%
|
$82,600
$118.31 P/Share
|
|
Feb 10
2025
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
980
-0.71%
|
$115,640
$118.39 P/Share
|
|
Feb 10
2025
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
911
-2.14%
|
$107,498
$118.25 P/Share
|
|
Feb 10
2025
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
980
-2.84%
|
$115,640
$118.27 P/Share
|
|
Feb 10
2025
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
980
-2.24%
|
$115,640
$118.31 P/Share
|
|
Feb 08
2025
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,329
+6.37%
|
-
|
|
Feb 08
2025
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,318
+0.82%
|
-
|
|
Feb 08
2025
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,860
+5.15%
|
-
|
|
Feb 08
2025
|
David W. Boyer Chief Corp. Affairs Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,329
+33.0%
|
-
|
|
Feb 08
2025
|
Kyle Gano Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,860
+1.32%
|
-
|
|
Feb 08
2025
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,727
+3.9%
|
-
|
|
Feb 08
2025
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,860
+5.11%
|
-
|
|
Feb 08
2025
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,860
+4.08%
|
-
|
|
Feb 03
2025
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
623
-15.33%
|
$92,827
$149.29 P/Share
|
|
Feb 03
2025
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,179
+22.48%
|
-
|
|
Jan 31
2025
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,740
-4.46%
|
$264,480
$152.89 P/Share
|
|
Jan 31
2025
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,740
+8.03%
|
-
|
|
Jan 31
2025
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,457
-4.31%
|
$221,464
$152.8 P/Share
|
|
Jan 31
2025
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,769
+7.57%
|
-
|
|
Jan 31
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
2,707
-0.52%
|
$411,464
$152.92 P/Share
|
|
Jan 31
2025
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,141
+0.98%
|
-
|
|
Jan 31
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
126
-0.8%
|
$19,152
$152.97 P/Share
|
|
Jan 31
2025
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
238
+1.49%
|
-
|
|
Jan 31
2025
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
422
-12.76%
|
$64,566
$153.05 P/Share
|